Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Staging of Heart Failure with Preserved Ejection Fraction
Author(s): Anastasia Shchendrygina , Ilya Giverts , Mariya Tokmakova , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
HFSA 24: FINEARTS-HF Across the Ejection Fraction Spectrum
Author(s): Akshay S Desai Added: 1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3… View more

Heart Failure
Autophagy and Endoplasmic Reticulum Stress in HFpEF
Author(s): Citrawati Dyah Kencono Wungu , Hendri Susilo , Cleodylon Reinard Susanto , et al Added: 2 months ago

MI/ACS

Prevention & Chronic Conditions
Liver Stiffness to Assess Central Venous Pressure in HF
Author(s): Nicolas Girerd Added: 10 months ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive… View more

Cardiovascular Renal Metabolic

Heart Failure
DIGIT-HF: Digitoxin Reduces Primary Outcome in Symptomatic Heart Failure with Reduced Ejection Fraction
Added: 7 months ago Source:  Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously… View more

Imaging & Diagnostics

Guidelines & Statements
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 1 year ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
Nothing to REFINE Yet
Author(s): Gheorghe-Andrei Dan Added: 4 months ago

Guidelines & Statements

Heart Failure
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 11 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 11 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure